1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Saved in:
| Title: | 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma. |
|---|---|
| Authors: | Johnson TS; Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA.; Indiana Biosciences Research Institute, Indianapolis, IN, USA.; Melvin and Bren Simon Comprehensive Cancer Center, Experimental and Developmental Therapeutics, School of Medicine, Indiana University, Indianapolis, IN, USA.; Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, USA., Sudha P; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA., Liu E; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA., Becker N; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA., Robertson S; Indiana Biosciences Research Institute, Indianapolis, IN, USA., Blaney P; Perlmutter Cancer Center, Langone Health, New York University, New York, NY, USA., Morgan G; Perlmutter Cancer Center, Langone Health, New York University, New York, NY, USA., Chopra VS; Genentech Inc., South San Francisco, CA, USA., Dos Santos C; Genentech Inc., South San Francisco, CA, USA., Nixon M; Roche Inc., Indianapolis, IN, USA., Huang K; Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA.; Melvin and Bren Simon Comprehensive Cancer Center, Experimental and Developmental Therapeutics, School of Medicine, Indiana University, Indianapolis, IN, USA.; Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, USA., Suvannasankha A; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA.; Roudebush VAMC, Indianapolis, IN, USA., Zaid MA; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA., Abonour R; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA., Walker BA; Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, USA. bw75@iu.edu.; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA. bw75@iu.edu. |
| Source: | Nature communications [Nat Commun] 2024 May 16; Vol. 15 (1), pp. 4144. Date of Electronic Publication: 2024 May 16. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-48327-9 |
